[{"id":"2c6b4f69-4124-49bc-8cc4-6915ea81dc11","acronym":"INDUCE-1","url":"https://clinicaltrials.gov/study/NCT02723955","created_at":"2021-01-17T17:58:41.023Z","updated_at":"2025-02-25T16:04:31.793Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","source_id_and_acronym":"NCT02723955 - INDUCE-1","lead_sponsor":"GlaxoSmithKline","biomarkers":" MSI • ICOS","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998"],"overall_status":"Completed","enrollment":" Enrollment 829","initiation":"Initiation: 06/23/2016","start_date":" 06/23/2016","primary_txt":" Primary completion: 07/05/2023","primary_completion_date":" 07/05/2023","study_txt":" Completion: 07/05/2023","study_completion_date":" 07/05/2023","last_update_posted":"2024-12-27"},{"id":"a50bebe7-8e32-4c0b-9893-640d44c45b2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03447314","created_at":"2021-01-18T16:59:51.495Z","updated_at":"2024-07-02T16:35:49.098Z","phase":"Phase 1","brief_title":"Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03447314","lead_sponsor":"GlaxoSmithKline","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • feladilimab (GSK3359609) • GSK1795091 • GSK3174998"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 03/11/2022","study_completion_date":" 03/11/2022","last_update_posted":"2023-05-03"},{"id":"a3e150d0-f86d-483c-a9d5-c8a944cf1fd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02528357","created_at":"2021-01-18T12:13:30.435Z","updated_at":"2025-02-25T16:15:02.032Z","phase":"Phase 1","brief_title":"GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)","source_id_and_acronym":"NCT02528357","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GSK3174998"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 09/11/2015","start_date":" 09/11/2015","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 04/29/2020","study_completion_date":" 04/29/2020","last_update_posted":"2021-05-18"}]